Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Based upon FDA's recent guidance and the Company's successful End of Phase 2 Meeting, Medimetriks will also reduce the size of its MM36 (difamilast) Phase 3 pivotal trial program by approximately 80%.
Lead Product(s): Difamilast
Therapeutic Area: Dermatology Product Name: MM36
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020